Superior Efficacy of Infliximab Versus Adalimumab for First-Line Treatment of Crohn’s Perianal Fistulae

By sjmartinez • August 5, 2023

Maas L, Gao R, Cusumano V, Spartz E, Chowdhury R, Krishna M, Lazarev M, Melia J, Selaru F, Sharma S, Limketkai B, Parian A. Superior Efficacy of Infliximab Versus Adalimumab for First-Line Treatment of Crohn's Perianal Fistulae. Dig Dis Sci. 2023 Aug 4. doi: 10.1007/s10620-023-08060-7. Epub ahead of print. PMID: 37540392.

Tags: Crohn’s disease, Digestive Diseases, General Internal Medicine, inflammatory bowel disease, Perianal disease, Perianal fistula, Publications, Resident, Tumor necrosis factor inhibitor

The PTPN2 rs1893217 IBD risk allele increases susceptibility to AIEC invasion by a JAK-STAT-CEACAM6 axis

Chatterjee P, Canale V, King SJ, Shawki A, Lei H, Santos AN, Haddad M, Gries C, McGovern DPB, Borneman J, McCole DF. The PTPN2 rs1893217 IBD risk[...]

Distal esophageal acid exposure and poor esophageal clearance correlate with probability of progression in Barrett’s esophagus as determined by the tissue systems pathology test

Eriksson SE, Kolb JM, Nguyen J, Sarici IS, Zheng P, Ayazi S. Distal esophageal acid exposure and poor esophageal clearance correlate with probability of progression[...]

Impact of Short Duration FODMAP Restriction on Breath Gases and Gastrointestinal Symptoms

Pathipati MP, Shortt A, Shortt C, McBride B, O'Rourke L, Burke R, Chey WD, Chang L, Staller K. Impact of Short Duration FODMAP Restriction on[...]